Mylan's EpiPen According to onefederal analysis, taxpayers may have overpaid for Mylan's EpiPen byas much as $1.27 billion over 10 years as a result of itsmisclassification. (Photo: Shutterstock)

Senators Ron Wyden, D-Oregon, and Chuck Grassley, R-Iowa, haveintroduced a bill that's aimed at the methods drug companies use toovercharge taxpayers for Medicaid rebates.

As The Hill reports, the bill, put forward by theincoming chairman and ranking member of the Senate FinanceCommittee, could mean that the two are looking for common ground ondrug prices.

Continue Reading for Free

Register and gain access to:

  • Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
  • Educational webcasts, white papers, and ebooks from industry thought leaders
  • Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Marlene Satter

Marlene Y. Satter has worked in and written about the financial industry for decades.

Core and Group Health
Health Care Reform
Cost-Containment